Advertisement

High-Altitude Research and Its Practical Clinical Application

  • Gustavo Zubieta-CastilloSr.
  • Gustavo Zubieta-CallejaJr.
Chapter

Abstract

Upon arriving above 2,500 m, the organism compensates the diminished inspired oxygen partial pressure by increasing ventilation and cardiac output. The pneumodynamic pump moves more rarefied air into the alveoli through an increase of the respiratory frequency and the tidal volume. Likewise, the hemodynamic pump increases both the cardiac frequency and the stroke volume, as if exercise were performed at sea level. The two pumps, one for air and the other for blood, carry out the essential role of supplying sufficient oxygen to the tissues and increasing the energy consumption until the red blood cells take over. The acid–base status, adequately interpreted at high altitude through the titratable hydrogen ion difference, along with the adaptation formula and multiple cellular changes, gives rise to adaptation. The tolerance to hypoxia formula reflects and explains the paradoxical concept that resistance to hypoxia grows as one goes higher. The possibility that man can adapt to live in the hypoxic environment of the summit of Mt. Everest is exposed. Furthermore, the knowledge of life at high altitude is proposed as an alternative to the environment of space travel. Herein, we describe our 43 years of experience and discoveries with fundamental concepts that change the way disease is treated in the hypoxic environment of high altitude.

Keywords

High Altitude Acute Mountain Sickness Chronic Mountain Sickness Oxygen Dissociation Curve Extreme Altitude 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Bert P (1978) Barometric pressure. Undersea Medical Society, BethesdaGoogle Scholar
  2. 2.
    De Santo NG, Cirillo M, Kirsch KA, Correale G, Drummer C, Frassl W et al (2005) Anemia and erythropoietin in space flights. Semin Nephrol 25:379–387PubMedCrossRefGoogle Scholar
  3. 3.
    Grocott MP, Martin DS, Levett DZ, McMorrow R, Windsor J, Montgomery HE (2009) Arterial blood gases and oxygen content in climbers on Mount Everest. N Engl J Med 360:140–149PubMedCrossRefGoogle Scholar
  4. 4.
    Leon-Velarde F, Gamboa A, Chuquiza JA, Esteba WA, Rivera-Chira M, Monge CC (2000) Hematological parameters in high altitude residents living at 4,355, 4,660, and 5,500 meters above sea level. High Alt Med Biol 1:97–104PubMedCrossRefGoogle Scholar
  5. 5.
    Leon-Velarde F, Maggiorini M, Reeves JT, Aldashev A, Asmus I, Bernardi L et al (2005) Consensus statement on chronic and subacute high altitude diseases. High Alt Med Biol 6:147–157PubMedCrossRefGoogle Scholar
  6. 6.
    NASA Crew Compartment Cabin Pressurization (2007) spaceflight.nasa.gov/shuttle/reference/shutref/orbiter/eclss/cabinpress.html. Accessed 15 Jun 2014
  7. 7.
    Neville J (1974) Hemoglobin oxygen affinity measurement using biotonometry. J Appl Physiol 37:961–971Google Scholar
  8. 8.
    Paulev PE, Zubieta-Calleja GR (2005) Essentials in the diagnosis of acid-base disorders and their high altitude application. J Physiol Pharmacol 56(Suppl 4):155–170PubMedGoogle Scholar
  9. 9.
    Rice L, Alfrey CP (2005) The negative regulation of red cell mass by neocytolysis: physiologic and pathophysiologic manifestations. Cell Physiol Biochem 15:245–250PubMedCrossRefGoogle Scholar
  10. 10.
    Tavassoli M (1982) Anemia of spaceflight. Blood 60:1059–1067PubMedGoogle Scholar
  11. 11.
    Zubieta-Calleja G (2004) Bloodletting: a medical resource since the stone age. J Qinghai Med Coll 25:273–275Google Scholar
  12. 12.
    Zubieta-Calleja G, Zubieta-Castillo G (1998) Changes in oximetry during breath holding in normal residents of high altitude. In: Hideki Ohno, Toshio Kobayashi, Shigeru Masuyama and Michiro Nakashima (eds) Progress in mountain medicine and high altitude physiology. Press Committee of the 3rd World Congress on Mountain Medicine and High Altitude Physiology, Matsumoto, pp 343–348Google Scholar
  13. 13.
    Zubieta-Calleja G, Zubieta-Castillo G, Zubieta-Calleja L, Zubieta N (2002) Measurement of circulatory time using pulse oximetry during breath holding in chronic hypoxia. HAMB 3:115Google Scholar
  14. 14.
    Zubieta-Calleja GJ, Paulev P-E, Mehrishi JN, Zubieta-Castillo G Sr (2012) Extremely high altitude hypoxic conditions during Mount Everest expeditions, residence at South Pole stations, in Tibet and among the Andes: Van Slyke equation modification is crucially important for acid–base measurements. JBPC 12:103–112CrossRefGoogle Scholar
  15. 15.
    Zubieta-Calleja GR (2007) Human adaptation to high altitude and to sea level: acid-base equilibrium, ventilation, and circulation in chronic hypoxia. Thesis. University of Copenhagen, CopenhagenGoogle Scholar
  16. 16.
    Zubieta-Calleja GR, Ardaya G, Zubieta N, Paulev PE, Zubieta-Castillo G (2013) Tolerance to hypoxia. J Fisiol 59(4): 65–72Google Scholar
  17. 17.
    Zubieta-Calleja GR, Paulev P-E, Zubieta-Calleja L, Zubieta-Castillo G (2007) Altitude adaptation through hematocrit changes. J Physiol Pharmacol 58:811–818PubMedGoogle Scholar
  18. 18.
    Zubieta-Calleja GR, Paulev PE, Zubieta-Calleja L, Zubieta-Calleja N, Zubieta-Castillo G (2006) Hypoventilation in chronic mountain sickness: a mechanism to preserve energy. J Physiol Pharmacol 57(Suppl 4):425–430PubMedGoogle Scholar
  19. 19.
    Zubieta-Calleja GR, Zubieta-Castillo G, Zubieta-Calleja L (1995) Inadequate treatment of excessive erythrocytosis. Acta Andina 4:123–126Google Scholar
  20. 20.
    Zubieta-Castillo G Sr, Zubieta-Calleja GR Jr, Zubieta-Calleja L, Zubieta N (2004) How chronic mountain sickness (cms) contributed to the theory of life at the hypoxic levels of the summit of mount Everest. HAMB 5:291–292Google Scholar
  21. 21.
    Zubieta-Castillo G Sr, Zubieta-Calleja GR Jr, Zubieta-Calleja L (2006) Chronic mountain sickness: the reaction of physical disorders to chronic hypoxia. J Physiol Pharmacol 57(Suppl 4):431–442PubMedGoogle Scholar
  22. 22.
    Zubieta-Castillo G, Zubieta-Calleja G (1996) Triple hypoxia syndrome. Acta Andina 5:15–18Google Scholar
  23. 23.
    Zubieta-Castillo G, Zubieta-Calleja G, Arano E, Zubieta-Calleja L (1998) Respiratory disease, chronic mountain sickness and gender differences at high altitude. In: Ohno H, Kobayashi T, Masuyama S, Nakashima M (eds) Progress in mountain medicine and high altitude physiology. Press Committee of the 3rd World Congress on Mountain Medicine and High Altitude Physiology, Matsumoto, pp 132–137Google Scholar
  24. 24.
    Zubieta-Castillo G, Zubieta-Calleja GR (2007) Facts that prove that adaptation to life at extreme altitude (8848 m) is possible. In: Lukyanova L, Takeda N, Singal PK (eds) Adaptation biology and medicine: health potentials, vol 5. Narossa Publishing House, New DehliGoogle Scholar
  25. 25.
    Zubieta-Castillo G, Zubieta-Calleja GR (1988) Iatrogenic disease in a polycythemic patient at altitude. Am Rev Respir Dis 137:509Google Scholar
  26. 26.
    Zubieta-Castillo G, Zubieta-Calleja GR (1988) The triple hypoxia syndrome at altitude (abstract). Am Rev Respir Dis 137:509Google Scholar
  27. 27.
    Zubieta-Castillo G, Zubieta-Calleja GR, Zubieta-Calleja L, Zubieta C, Nancy (2003) Adaptation to life at the altitude of the summit of Everest. Fiziol Zh 49:110–117PubMedGoogle Scholar

Copyright information

© Springer India 2014

Authors and Affiliations

  • Gustavo Zubieta-CastilloSr.
    • 1
  • Gustavo Zubieta-CallejaJr.
    • 1
  1. 1.High Altitude Pulmonary and Pathology Institute (IPPA)La PazBolivia

Personalised recommendations